Efficacy of Platelet Rich Plasma for Treatment of Muscle Rupture With Haematoma (PRP-RICE)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01440725|
Recruitment Status : Completed
First Posted : September 26, 2011
Last Update Posted : January 10, 2013
This is a multicenter, simple blind, masking of outcomes assessors, parallel, randomised clinical trial in patient with muscle rupture and with hematoma production. The main hypothesis is that infiltration in the area of muscle injury in autologous platelet-rich plasma (PRP)improves muscle regeneration and repair by shortening the time to complete recovery.
The main objective is to evaluate the PRP for healing muscular lesions 'tennis leg' type or distal rectus femoral. The secondary objectives are: to evaluate the risk of lesion recurrence; to evaluate the quality of lesion recovery process and evaluate intervention's safety.
Experimental treatment will be the administration of PRP autologous (4-8 cc in a unique dose) by muscular infiltration en the empty space generated after the hematoma evacuation. Control treatment will be hematoma evacuation. Both treatment groups will use compressive bandage and they will recommend rest, extremity elevation, local ice and lately physiotherapy.
Size sample: 76 patients (38 in each group)
|Condition or disease||Intervention/treatment||Phase|
|Muscle Injuries||Biological: Autologous Platelet-rich plasma (PRP) Procedure: Evacuation of haematoma||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||71 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Outcomes Assessor)|
|Official Title:||Multicenter Double Blind, With Evaluator Blinding, Parallel, Randomized Clinical Trial, to Assess the Efficacy of Platelet Rich Plasma for Treatment of Muscle Rupture With Haematoma|
|Study Start Date :||October 2009|
|Primary Completion Date :||December 2012|
|Study Completion Date :||December 2012|
Administration of 4-8cc of autologous Platelet-rich plasma (PRP)into the muscle wound after the evacuation of the haematoma.
Biological: Autologous Platelet-rich plasma (PRP)
4-8cc, a single dose
Active Comparator: Evacuation of haematoma
Evacuation of the hematoma, and simulation of the administration of PRP
Procedure: Evacuation of haematoma
Evacuation of the haematoma, a single procedure
Other Name: Drainage of haematoma
- Time to complete recover of muscular lesions [ Time Frame: weekely assessment during 8 weeks ]The complete recovering will be when the patient does his habitual activity.
- Percentage of muscular lesion recurrence. [ Time Frame: During all study (one year of follow-up) ]
Percentage of patients with muscular lesion recurrence.
Muscular lesion recurrence will be considered if there are symptoms and a lesion gap by ultra sound scan.
- Percentage of healing [ Time Frame: 8 weeks ]Percentage of patients with the healed lesion
- Quality of the regenerated area [ Time Frame: at 8 week ]By ultrasonography, the characteristics of the wound will be quantified (size, fibrosis)
- Pain [ Time Frame: 12 months ]The pain will be measured by a VAS each week, the first 8 weeks of the study and, at 6 and 12 month.
- Adverse effects to treatments [ Time Frame: 12 months ]Adverse effects will be assessed each week, the first 8 weeks of the study and, at 6 and 12 month.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01440725
|Centro Cochrane Iberoamericano|
|Barcelona, Spain, 08041|
|Principal Investigator:||Martínez Zapata, Mª José||Centro Cochrane Iberoamericano. Servicio de Epidemiología Clínica y Salud Pública. IIB Sant Pau|
|Principal Investigator:||Orozco Delclòs, LLuís||Institut de Teràpia Regenerativa i Tissular. Centro Médico Teknon. Barcelona|